Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04772235
Title Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Instituto Oncologico Dr Rosell

lung non-squamous non-small cell carcinoma


Osimertinib + Repotrectinib

Age Groups: adult | senior
Covered Countries ESP

No variant requirements are available.